Biostatistics statement

Title: Regorafenib combined with programmed cell death-1 inhibitor against refractory colorectal cancer and the platelet-to-lymphocyte ratio's prediction on effectiveness

MS Number: 72117

The statistical methods of this study were reviewed by a member of the Biostatistic Service from the Department of Biostatistics, Zhongshan Hospital, Fudan University, Shanghai, China.

Name: Fei Liang
Signature:
Fei Liang
Contact information: Email: liangfei0726@163.com